Sarepta Therapeutics
Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
SRPT Key Statistics
Stock Snapshot
As of today, Sarepta Therapeutics(SRPT) shares are valued at $19.97. The company's market cap stands at 2.11B, with a P/E ratio of -20.70.
During the trading session on 2026-05-09, Sarepta Therapeutics(SRPT) shares reached a daily high of $21.12 and a low of $19.87. At a current price of $19.97, the stock is +0.5% higher than the low and still -5.4% under the high.
Trading volume for Sarepta Therapeutics(SRPT) stock has reached 4.08M, versus its average volume of 2.98M.
Over the past 52 weeks, Sarepta Therapeutics(SRPT) stock has traded between a high of $44.14 and a low of $10.42.
Over the past 52 weeks, Sarepta Therapeutics(SRPT) stock has traded between a high of $44.14 and a low of $10.42.
SRPT News
If you are wondering whether Sarepta Therapeutics at US$20.80 is starting to look like value or still carries too much risk, the recent share price and fundamen...
J.P. Morgan analyst Anupam Rama has maintained their neutral stance on SRPT stock, giving a Hold rating today. Anupam Rama has given his Hold rating due to a c...
Needham analyst Gil Blum has maintained their bearish stance on SRPT stock, giving a Sell rating today. Gil Blum has given his Sell rating due to a combination...
Analyst ratings
48%
of 27 ratingsMore SRPT News
In a report released yesterday, Yigal Nochomovitz from Citi maintained a Sell rating on Sarepta Therapeutics, with a price target of $13.00. Claim 55% Off TipRa...
Reports Q1 revenue $730.8M, consensus $475.01M. “We entered 2026 with clear priorities-stabilizing the business, restoring growth, maintaining financial strengt...
Image source: The Motley Fool. Wednesday, May 6, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Douglas Ingram President, Research and Develo...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.